119: 25-Hydroxyvitamin D and Inflammation and Its Association with Hemoglobin Levels in Chronic Kidney Disease

2008 ◽  
Vol 51 (4) ◽  
pp. B57 ◽  
Author(s):  
Jessica Kendrick ◽  
Gerard Smits ◽  
Michel Chonchol
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial

2016 ◽  
Vol 116 (12) ◽  
pp. 2074-2081 ◽  
Author(s):  
James B. Wetmore ◽  
Cassandra Kimber ◽  
Jonathan D. Mahnken ◽  
Jason R. Stubbs
Keyword(s):  
Clinical Trial ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mineral Metabolism ◽  
Substantial Reduction ◽  
Randomised Clinical Trial ◽  
Optimal Method ◽  
Hydroxyvitamin D ◽  
Significant Difference ◽  
25 Hydroxyvitamin D

AbstractPatients with chronic kidney disease (CKD) demonstrate complex mineral metabolism derangements and a high prevalence of vitamin D deficiency. However, the optimal method of 25-hydroxyvitamin D (25(OH)D) repletion is unknown, and trials analysing the comparative efficacy of cholecalciferol and ergocalciferol in this population are lacking. We conducted a randomised clinical trial of cholecalciferol 1250μg (50 000 IU) weekly v. ergocalciferol 1250μg (50 000 IU) weekly for 12 weeks in forty-four non-dialysis-dependent patients with stage 3–5 CKD. The primary outcome was change in total 25(OH)D from baseline to week 12 (immediately after therapy). Secondary analyses included the change in 1,25-dihydroxyvitamin D (1,25(OH)2D), parathyroid hormone (PTH), D2 and D3 sub-fractions of 25(OH)D and 1,25(OH)2D and total 25(OH)D from baseline to week 18 (6 weeks after therapy). Cholecalciferol therapy yielded a greater change in total 25(OH)D (45·0 (sd 16·5) ng/ml) v. ergocalciferol (30·7 (sd 15·3) ng/ml) from baseline to week 12 (P<0·01); this observation partially resulted from a substantial reduction in the 25(OH)D3 sub-fraction with ergocalciferol. However, following cessation of therapy, no statistical difference was observed for total 25(OH)D change from baseline to week 18 between cholecalciferol and ergocalciferol groups (22·4 (sd 12·7) v. 17·6 (sd 8·9) ng/ml, respectively; P=0·17). We observed no significant difference between these therapies with regard to changes in serum PTH or 1,25(OH)2D. Therapy with cholecalciferol, compared with ergocalciferol, is more effective at raising serum 25(OH)D in non-dialysis-dependent CKD patients while active therapy is ongoing. However, levels of 25(OH)D declined substantially in both arms following cessation of therapy, suggesting the need for maintenance therapy to sustain levels.

scholarly journals Serum 25-hydroxyvitamin D level is negatively associated with serum phosphorus level among stage 3a-5 chronic kidney disease patients

Nefrología ◽  
2018 ◽  
Vol 38 (5) ◽  
pp. 514-519
Author(s):  
Ahmed Fayed ◽  
Mahmoud M. El Nokeety ◽  
Ahmed A. Heikal ◽  
Khaled Marzouk ◽  
Hany Hammad ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Serum Phosphorus ◽  
Phosphorus Level ◽  
Serum Phosphorus Level ◽  
Negatively Associated ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Urine albumin and serum uric acid are important determinants of serum 25 hydroxyvitamin D level in pre-dialysis chronic kidney disease patients

Renal Failure ◽  
2019 ◽  
Vol 41 (1) ◽  
pp. 540-546
Author(s):  
Ahmed Fayed ◽  
Mahmoud M. El Nokeety ◽  
Ahmed A. Heikal ◽  
Khaled M. Sadek ◽  
Hany Hammad ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Kidney Disease ◽  
Serum Uric Acid ◽  
Hydroxyvitamin D ◽  
Urine Albumin ◽  
25 Hydroxyvitamin D

25-Hydroxyvitamin D Deficiency and Inflammation and Their Association with Hemoglobin Levels in Chronic Kidney Disease

2009 ◽  
Vol 30 (1) ◽  
pp. 64-72 ◽  
Author(s):  
Jessica Kendrick ◽  
Giovanni Targher ◽  
Gerard Smits ◽  
Michel Chonchol
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Modifiers of Plasma 25-Hydroxyvitamin D and Chronic Kidney Disease Outcomes in Black Americans: The Jackson Heart Study

2019 ◽  
Vol 104 (6) ◽  
pp. 2267-2276 ◽  
Author(s):  
Joseph Lunyera ◽  
Clemontina A Davenport ◽  
Jane Pendergast ◽  
Solomon K Musani ◽  
Nrupen A Bhavsar ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Black Americans ◽  
Jackson Heart Study ◽  
Hydroxyvitamin D ◽  
Disease Outcomes ◽  
Heart Study ◽  
25 Hydroxyvitamin D
Sign in / Sign up

Export Citation Format

Share Document